Cardiovascular Risk FactorEpitwinNCT04279704
Overcoming Obstacles in Epigenetic Analysis of Human Twins
An observational study of Cardiovascular Risk Factor, run by Baylor College of Medicine at 1 site in United States.
Trial summary
Background Cardiovascular disease is the leading cause of death in the U.S., however scientists have failed to learn fully what are the causes of this disease. A promising lead in understanding the origins of cardiovascular disease may be in gene expression changes occurring in utero in response to environmental… Read more about this study
- Who is it for?
- Ages 1 month to 6 monthsHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Risk Factor
- How many people
- 80 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2016to 1 Mar 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 month to 6 months
- All sexes
- Healthy volunteers accepted
- Child
Study population: Study population include preterm and full term infants who are monozygotic twins newborn to six months of age, recruited from Texas Children's Hospital, Houston.
Who may be able to join
- Monozygotic (preterm or full term) twin infants.
Who cannot join
- Infants with major congenital anomalies. Infants from higher birth order (e.g. triplets etc.)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Overcoming Obstacles in Epigenetic Analysis of Human Twins: The Baylor Infant Twin Study
Background Cardiovascular disease is the leading cause of death in the U.S., however scientists have failed to learn fully what are the causes of this disease. A promising lead in understanding the origins of cardiovascular disease may be in gene expression changes occurring in utero in response to environmental (non-genetic) factors. Such changes govern whether a gene is turned on or turned off during an individual's lifetime. Twin pregnancies and twin infants help researchers to have a better understanding of whether the gene expression changes are genetic or environmental in origin. Therefore, the purpose of this project is to examine which body tissues (such as hair, fingernails, urine or blood) are needed to accurately study how gene activity is affected by prenatal factors.
Read the detailed description
Cardiovascular disease (CVD) is the leading cause of death in the US, emphasizing an incomplete understanding of its pathology and translation into effective interventions. The fetal origins hypothesis posits that the risk of CVD is partially set in utero. Individual differences in epigenetic DNA methylation are a leading candidate mechanism to explain the association between CVD risk and the fetal environment. Indeed, differences in DNA methylation have been implicated in the pathogenesis of CVD and its risk factors. Previous studies in rats have been characterizing a specific class of epigenetic loci known as metastable epialleles (MEs). Methylation of DNA in utero can be in response to non-genetic factors and the degree of hypo- or hyper- methylation remains stable throughout the lifespan. Studies in mice further have shown that methylation has dramatic and permanent phenotypic effects. In recent studies over 100 human MEs have been identified. Several of these loci have been associated with phenotypes related to CVD risk.
Investigators now need to determine the phenotypic consequences of interindividual variation in DNA methylation at human MEs. Studies in inbred mice have been instrumental in showing that there are non-genetic influences on the establishment of methylation at MEs. Twin studies, typically using saliva or peripheral blood cells (PBCs), have been used to assess whether individual epigenetic variation in humans is influenced by non-genetic factors. Indeed, in translating epigenetic findings from mice to humans, monozygotic (MZ; genetically-identical) twins are commonly viewed as the human equivalent of isogenic mice. However, there is an important difference between MZ twins and isogenic mice. Whereas each inbred mouse littermate has its own placenta, about 75% of MZ twins share a single placenta (monochorionicity) and therefore have intermingled circulation during fetal development. It is therefore essential to determine whether the resulting "cross pollination" of hematopoietic stem cells (HSCs) results in peripheral blood (and salivary) DNA of two monochorionic MZ twins being more epigenetically similar than that of other somatic tissues. Accurately quantifying epigenetic effects of periconceptional nutrition in twin studies, and thereby providing future intervention targets to reduce CVD risk in offspring, will likely require analyses of DNA methylation in tissues other than saliva or peripheral blood cells.
Investigators need to examine whether Monozygotic:Dizygotic twin comparisons, without regard to placental sharing in utero (chorionicity), are a suitable model for future work which will characterize ME loci and establish their associations with phenotypic consequences. Infancy is the ideal time to examine the association between MEs and CVD factors, since it provides the earliest time for risk prediction and intervention. Therefore, for this study investigators plan to recruit 40 twins pairs under 4 months of age to identify more easily available tissues for epigenetic analyses than hair follicles (which has been previously used as an alternative to PBCs or saliva). The plucking of hair follicles from infants is too burdensome on participants to accrue the large samples intended for future analyses.
Summary: Studies in rats provide evidence that maternal nutrition around the time of conception can alter epigenetic mechanisms affecting obesity, and obesity itself is a strong CVD risk factor. This relationship is mediated by the early embryonic methylation at metastable alleles. Following the identification of over 100 MEs in humans many of which are associated with obesity or other CVD risk factors, investigators are now ready to implement studies to examine whether periconceptional nutrition influences CVD risk via methylation. Investigators seek to translate this work on MEs into human populations since it suggests an important CVD risk. Further, investigators want to establish the importance of chorionicity as a factor in epigenetic analyses of MZ twins, and to validate a new tissue for such studies.
Aim 1: Validate nail clippings as an acceptable DNA source for the study for human MEs Hypothesis 1: At MEs, DNA methylation in infant nail clippings (which can be easily collected) is highly correlated with that in hair follicles, urine and buccal swabs.
Aim 2: Compare epigenetic discordance at MEs in monochorionic vs. dichorionic MZ twins Hypothesis 2: At MEs, dichorionic MZ twin pairs (with separate placentae) will show greater epigenetic dissimilarity in PBCs than monochorionic MZ twin pairs (which share a placenta), but not in other tissues.
- Conditions
- Cardiovascular Risk Factor
- Keywords
- Metastable epialleles, Monozygotic, Epigenetic, Twins, DNA methylation, Genetic
What is being measured
The primary outcome is the main question the study is designed to answer.
DNA methylations
Percent DNA methylations at metastable epialleles for each sample (urine, finger nails, peripheral blood cells, hair follicles and buccal swab).
Measured: 1 hour
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2020
- Study startSep 2016
- Primary completionMar 2020
- Study completion1 Mar 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular Risk FactorStudies of the same condition, open and under way.
- More trials run by Baylor College of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Baylor College of Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- National Institutes of Health (NIH)
- Responsible party
- Principal investigator, Alexis Wood, Baylor College of Medicine
- Investigators
- Alexis C Wood, PhD, Principal investigator, Baylor College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04279704
- Sponsor's protocol ID
- H 37359
- Acronym
- Epitwin
- Status last verified
- Oct 2020
- First submitted
- 30 Jan 2020
- Last updated
- 28 Oct 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Overcoming Obstacles in Epigenetic Analysis of Human Twins: The Baylor Infant Twin Study
- ClinicalTrials.gov ID
- NCT04279704
- Acronym / sponsor ID
- Epitwin / H 37359
- Conditions
- Cardiovascular Risk Factor
- Keywords
- Metastable epialleles, Monozygotic, Epigenetic, Twins, DNA methylation, Genetic
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Baylor College of MedicineUniversity, hospital or other
- Collaborators
- National Institutes of Health (NIH)
- Study start
- Sep 2016 (actual)
- Primary completion
- Mar 2020 (actual)
- Study completion
- 1 Mar 2020 (actual)
- First posted
- 21 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background Cardiovascular disease is the leading cause of death in the U.S., however scientists have failed to learn fully what are the causes of this disease. A promising lead in understanding the origins of cardiovascular disease may be in gene expression changes occurring in utero in response to environmental (non-genetic) factors. Such changes govern whether a gene is turned on or turned off during an individual's lifetime. Twin pregnancies and twin infants help researchers to have a better understanding of whether the gene expression changes are genetic or environmental in origin. Therefore, the purpose of this project is to examine which body tissues (such as hair, fingernails, urine or blood) are needed to accurately study how gene activity is affected by prenatal factors.
Detailed description
Cardiovascular disease (CVD) is the leading cause of death in the US, emphasizing an incomplete understanding of its pathology and translation into effective interventions. The fetal origins hypothesis posits that the risk of CVD is partially set in utero. Individual differences in epigenetic DNA methylation are a leading candidate mechanism to explain the association between CVD risk and the fetal environment. Indeed, differences in DNA methylation have been implicated in the pathogenesis of CVD and its risk factors. Previous studies in rats have been characterizing a specific class of epigenetic loci known as metastable epialleles (MEs). Methylation of DNA in utero can be in response to non-genetic factors and the degree of hypo- or hyper- methylation remains stable throughout the lifespan. Studies in mice further have shown that methylation has dramatic and permanent phenotypic effects. In recent studies over 100 human MEs have been identified. Several of these loci have been associated with phenotypes related to CVD risk.
Investigators now need to determine the phenotypic consequences of interindividual variation in DNA methylation at human MEs. Studies in inbred mice have been instrumental in showing that there are non-genetic influences on the establishment of methylation at MEs. Twin studies, typically using saliva or peripheral blood cells (PBCs), have been used to assess whether individual epigenetic variation in humans is influenced by non-genetic factors. Indeed, in translating epigenetic findings from mice to humans, monozygotic (MZ; genetically-identical) twins are commonly viewed as the human equivalent of isogenic mice. However, there is an important difference between MZ twins and isogenic mice. Whereas each inbred mouse littermate has its own placenta, about 75% of MZ twins share a single placenta (monochorionicity) and therefore have intermingled circulation during fetal development. It is therefore essential to determine whether the resulting "cross pollination" of hematopoietic stem cells (HSCs) results in peripheral blood (and salivary) DNA of two monochorionic MZ twins being more epigenetically similar than that of other somatic tissues. Accurately quantifying epigenetic effects of periconceptional nutrition in twin studies, and thereby providing future intervention targets to reduce CVD risk in offspring, will likely require analyses of DNA methylation in tissues other than saliva or peripheral blood cells.
Investigators need to examine whether Monozygotic:Dizygotic twin comparisons, without regard to placental sharing in utero (chorionicity), are a suitable model for future work which will characterize ME loci and establish their associations with phenotypic consequences. Infancy is the ideal time to examine the association between MEs and CVD factors, since it provides the earliest time for risk prediction and intervention. Therefore, for this study investigators plan to recruit 40 twins pairs under 4 months of age to identify more easily available tissues for epigenetic analyses than hair follicles (which has been previously used as an alternative to PBCs or saliva). The plucking of hair follicles from infants is too burdensome on participants to accrue the large samples intended for future analyses.
Summary: Studies in rats provide evidence that maternal nutrition around the time of conception can alter epigenetic mechanisms affecting obesity, and obesity itself is a strong CVD risk factor. This relationship is mediated by the early embryonic methylation at metastable alleles. Following the identification of over 100 MEs in humans many of which are associated with obesity or other CVD risk factors, investigators are now ready to implement studies to examine whether periconceptional nutrition influences CVD risk via methylation. Investigators seek to translate this work on MEs into human populations since it suggests an important CVD risk. Further, investigators want to establish the importance of chorionicity as a factor in epigenetic analyses of MZ twins, and to validate a new tissue for such studies.
Aim 1: Validate nail clippings as an acceptable DNA source for the study for human MEs Hypothesis 1: At MEs, DNA methylation in infant nail clippings (which can be easily collected) is highly correlated with that in hair follicles, urine and buccal swabs.
Aim 2: Compare epigenetic discordance at MEs in monochorionic vs. dichorionic MZ twins Hypothesis 2: At MEs, dichorionic MZ twin pairs (with separate placentae) will show greater epigenetic dissimilarity in PBCs than monochorionic MZ twin pairs (which share a placenta), but not in other tissues.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 1 month to 6 months
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- Study population include preterm and full term infants who are monozygotic twins newborn to six months of age, recruited from Texas Children's Hospital, Houston.
Key inclusion criteria (1 listed)
- Monozygotic (preterm or full term) twin infants.
Key exclusion criteria (1 listed)
- Infants with major congenital anomalies. Infants from higher birth order (e.g. triplets etc.)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
DNA methylations
Time frame: 1 hour
Percent DNA methylations at metastable epialleles for each sample (urine, finger nails, peripheral blood cells, hair follicles and buccal swab).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2020.
- Individual participant dataSharing planned: No
Related trials for Cardiovascular Risk Factor
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Overweight, Prediabetic State
RecruitingObservational study
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Metabolic Disease, Obesity
Not yet recruiting
Multimodal AI-Driven Out-of-Hospital Management for Hypertension and Cardiometabolic Risk
Hypertension, Hyperglycemia
Recruiting
Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)
Heart Failure, Cardiovascular Risk Factors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexis C Wood, PhD principal investigator
Baylor College of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Risk Factor, run by Baylor College of Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
DNA methylations (time frame: 1 hour). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2020.